Intangible Assets (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2021

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets, net of accumulated amortization, impairment charges and adjustments

	As of September 30, 2021									As of December 31, 2020
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
IPR&D Assets	$	38,876	$	(10,132	)	$	28,744	$	38,876	$	(8,399	)	$	30,477
Acquired patents		99		(99	)		—		99		(85	)		14
Total intangible assets	$	38,975	$	(10,231	)	$	28,744	$	38,975	$	(8,484	)	$	30,491

	As of December 31, 2020							As of December 31, 2019
	Cost		Accumulated Amortization*			Net		Cost		Accumulated Amortization*			Net
IPR&D Assets	$	38,876	$	(8,399	)	$	30,477	$	35,275	$	(7,624	)	$	27,651
Acquired patents		78		(64	)		14		78		(39	)		39
Total intangible assets	$	38,954	$	(8,463	)	$	30,491	$	35,353	$	(7,663	)	$	27,690

*        Accumulated Amortization of IPR&D Assets includes impairment charges as described below.

Schedule of individually material development projects in progress

	September 30, 2021 $	December 31, 2020 $
Stenoparib	25,957	27,522
Dovitinib	2,787	2,955
	28,744	30,477

	December 31,
	2020 $	2019 $
Stenoparib	27,522	24,970
Dovitinib	2,955	2,681
Total	30,477	27,651